NewsBenzingaFDA Clears QIAGEN's Gram-Negative QIAstat-Dx Bloodstream Panel, Joining Gram-Positive And Fungal Panel To Cover 33 Pathogen Targets And 28 Resistance Marker FDA Clears QIAGEN's Gram-Negative QIAstat-Dx Bloodstream Panel, Joining Gram-Positive And Fungal Panel To Cover 33 Pathogen Targets And 28 Resistance Marker Benzinga 2026.09.28 07:10 (GMT+0) Open on Benzinga Other news QCP: Bitcoin Faces Dual Pressure from Geopolitics and Macro Data, Key Support Levels in Focus Is CrowdStrike Stock Outperforming the S&P 500? Solana Developers Say “No Alpenrush” as Alpenglow Mainnet Launch Rumors Collapse Compound Foundation accused of improperly using 8.42 million DAI reserves Micron Heads Into Earnings With Memory Prices Still Climbing and Supply Nowhere Near Enough Piper Sandler Maintains Overweight on Tyler Technologies, Lowers Price Target to $450
